Objectives. We investigated whether serum levels of an alternatively spliced soluble (s)TNF receptor-2 (DS-TNFR2) affected the clinical response to anti-TNF-a therapy, classical DMARDs or radiological evidence of disease progression in patients with RA. (107) months] who started infliximab therapy. We evaluated the European League Against Rheumatism (EULAR) response to therapy and the serum levels of DS-TNFR2, sTNFR2 and ACPAs at baseline and at 12 months. In Cohort 1, radiological progression and levels of MMP-1 were also determined.
Introduction
RA is a systemic autoimmune disease characterized by polyarthritis, joint damage and functional disability. Networks of pro-inflammatory cytokines, chemokines and growth factors play a fundamental role in its pathogenesis [1] .
TNF-a is one of the most potent pro-inflammatory cytokines in RA. TNF-a regulates cell survival, death and/or growth, depending on the cell target. TNF-a signalling is mediated by high-affinity membrane-bound TNF receptors (TNFRs), TNFR1 (p55) and TNFR2 (p75). In a process known as shedding, the extracellular portions of these receptors are proteolytically cleaved to create soluble receptors (sTNFR1 and sTNFR2) [2] . Soluble receptors can also be expressed through alternative splicing of the receptor transcripts. Shedding and alternative splicing are not mutually exclusive mechanisms for producing soluble receptors. Other members of the TNFR family and several other soluble cytokine receptors are also generated by alternative splicing [3, 4] .
We recently identified a biologically active soluble spliced TNF-a receptor 2 isoform (DS-TNFR2) that was generated by alternative splicing. DS-TNFR2 antagonized TNF-a action in in vivo studies [5] . Quantification of this variant allowed, for the first time, determination of the proportion of sTNFR2 produced by shedding. A previous study by our group found that DS-TNFR2 was significantly higher in patients with septic shock compared with patients with RA [5] .
Serum sTNFR levels have been strongly correlated with disease activity and severity in RA [6] ; moreover, elevated levels of sTNFR2 are associated with a significantly increased risk of mortality, independently of other markers for RA activity and severity [7] . Furthermore, moderately high serum levels of sTNFR2 have been associated with the subsequent development of RA, primarily in postmenopausal women [8] .
Soluble TNF-a receptors are the natural homeostatic regulators of TNF-a action, because the degree of TNFa-driven inflammatory activity depends on the balance between TNF-a and sTNFRs [9] . Furthermore, the addition of exogenous sTNFRs in several animal models reduces the mortality due to endotoxin-induced shock [10] . Therefore, it is likely that individuals with high levels of sTNFRs would exhibit efficient antagonization of TNF-a biological activity. This could affect RA outcomes, including the response to therapy and radiographic evidence of disease progression. Therefore, we hypothesized that patients with high levels of DS-TNFR2 might have a different response to anti-TNF-a therapy and exhibit less radiographic evidence of progression than patients with normal DS-TNFR2 levels. We tested this hypothesis in two independent cohorts of patients with RA.
Patients and methods
This longitudinal prospective study included two groups of patients with RA who met the ACR criteria [11] .
Cohort 1
Cohort 1 included 52 DMARD-naïve patients with active early RA. All patients underwent a therapeutic protocol, including gold salts (i.m. sodium aurothiomalate, 50 mg/week) as the first-choice DMARD, together with methylprednisolone at 4 mg/day. Some patients received NSAIDs, preferentially indomethacin, and IA steroid therapy with triamcinolone hexacetonide or acetonide, according to clinical judgement. Therapy response was evaluated at 6 and 12 months. At 6 months, therapy was altered according to the patient response; when adverse effects and no clinical improvement or <20% improvement in the core data set (ACR20 response) were observed, MTX was instituted as DMARD monotherapy at increasing weekly doses of 7.520 mg; when a patient had an ACR50 response, including clinical remission, gold salts were administered every 23 weeks; when a patient had an ACR20 response but no ACR50 response, combination therapy with gold salts and MTX was initiated. Methylprednisolone therapy was tapered off according to clinical judgement [12] . Baseline and 12-month hand and foot radiographs were obtained and graded by the LarsenScott method [13] . Thirty-two joints were assessed, including bilateral thumb IP joints, PIP joints 25, MCP joints 15, big toe IP joints, MTP joints 25 and wrists. Each wrist was considered a unit, and its score multiplied by 5. Thus, the Larsen score ranged from 0 to 200. The erosion joint count (EJC) was defined as the number of joints, out of 32 total joints, with any evidence of cortical erosion. All radiographs were read by the same observer (R.S.) chronologically. As a measure of radiographic progression, we used the minimal clinically important difference (MCID) [14] , which was a change of 52 Larsen score units between baseline and 12 months. Any increase (one or more joints with erosions) in the EJC was also considered indicative of radiographic progression.
Cohort 2
Cohort 2 included 64 patients with active established RA refractory to MTX. Anti-TNF-a therapy was added to the treatment, and patients were followed for 30 weeks. Each participant signed a written informed consent. The study was approved by the ethics committee of the Hospital Clinic of Barcelona.
Disease activity
Disease activity was evaluated with clinical and biological parameters measured at baseline and at 12 months in Cohort 1, and at 6 and 30 weeks in Cohort 2. These included: the pain visual analogue scale; physician's and patient's global assessments; tender joint count and swollen joint count of 28 joints; modified HAQ (mHAQ) score; ESR (mm/h); CRP (by nephelometry in mg/dl); RF (by nephelometry; positive >50 UI/ml); 28-joint DAS (DAS-28); and the European League Against Rheumatism (EULAR) response to therapy. A EULAR response was considered as a dichotomic variable: at least moderate response vs non-response. We also determined serum levels of ACPAs, sTNFR2 and DS-TNFR2 in both groups. Finally, in Cohort 1, we determined the levels of MMP-1 at baseline and at 12 months, as a marker of radiographic progression.
ACPA levels ACPA levels were determined with the Immunoscan-RA Mark-2 ELISA test (Eurodiagnostica, Malmö , Sweden), according to the manufacturer's instructions. Levels >50 UI/ml were considered positive. sTNFR2 sTNFR2 was detected with the s-TNF-R (80 KDa) Human ELISA Module Set (Bender MedSystems, Vienna, Austria), according to the manufacturer's instructions. The sensitivity of the assay was 0.75 ng/ml.
DS-TNFR2
DS-TNFR2 was detected with an ELISA system that differentiated between the soluble receptor generated by alternative splicing (DS-TNFR2) and that generated by proteolytic cleavage (PC-TNFR2). This ELISA implemented a new monoclonal antibody against an epitope specific for DS-TNFR2 (first 14 residues of the juxtamembrane region), which is lacking in soluble PC-TNFR2 [5] . In order to demonstrate that this antibody did not cross-react with PC-TNFR2, we induced in vitro TNFR2 shedding with phorbol myristate acetate in various cells, including TNFR-2-transfected COS-7 cells, peripheral blood mononuclear cells (PBMCs) and U937 cells. The DS-TNFR2 ELISA did not detect TNFR2 shed from any of these cell types [5] . The sensitivity of the assay was 1.25 ng/ml.
High levels of DS-TNFR2 or sTNFR2 found in the sera of some patients were measured in the presence 5 mg/ml purified mouse IgG (Sigma, St Louis, MO, USA), in order to ensure that the result was not due to a reaction to the anti-mouse immunoglobulin G (IgG) antibodies.
MMP-1
Serum human MMP-1 was measured with the MMP-1 Human Biotrack ELISA System (Amersham Biosciencies, Buckinghamshire, UK) according to the manufacturer's instructions. The sensitivity of the MMP-1 assay was 1.7 ng/ml.
Statistical analysis
Comparisons between groups were made with the MannWhitney U-test, KruskalWallis test, analysis of variance (ANOVA) and Fisher's exact test. The Wilcoxon signed rank and McNemar tests were used to investigate changes within groups over time. Spearman's correlation coefficient was used to calculate bivariate correlations. Receiver operating characteristic (ROC) curves and their 95% CIs were performed to analyse the predictive power of the study variables on radiological progression. A logistic regression model was used to identify factors associated with maintenance of EULAR response over time. P < 0.05 was considered to be statistically significant. All analyses were performed with the SPSS v14 (SPSS< Chicago, IL, USA) and STATA v10 (Stata Corp., College Station, TX, USA) programs.
Results
In order to examine potential differences in the capacity to block serum TNF-a, we arbitrarily defined DS-TNFR2 >50 ng/ml to be high levels (HLs), and 450 ng/ml normal levels (NLs). Thus, RA patients were divided into groups with HL and NL DS-TNFR2. Confirming previous results [5] , in the HL group, 70% of total sTNFR2 comprised DS-TNFR2, with a high correlation between DS-TNFR2 and sTNFR2 levels. The results were not affected by the inclusion of mouse IgG, excluding the possibility of false-positive results. Furthermore, we did not detect similarly high levels of sTNFR1 with an identical ELISA assay (data not shown); therefore, HL status reflected elevated DS-TNFR2.
RA patients with HLs responded to therapy differently from those with NLs Cohort 1 patients were naive to DMARDs. They were aged 56 (13.5) years, 83% female, 81% positive for RF, 69.2% positive for ACPA and had had RA for 8.5 (6.2) months. Demographic, clinical and biological data are detailed in Table 1 (Fig. 1) . Analysis of the change in EULAR response during follow-up in patients with HLs at baseline showed no significant differences between Weeks 6 and 30 (exact McNemar significance probability = 1.000). However, the same analysis in patients with NLs at baseline showed significantly fewer responders at Week 30 (exact McNemar significance probability < 0.001).
Comparison of the percentage of patients with loss of EULAR response during follow-up in both groups (i.e. patients who responded at Week 6 but not at Week www.rheumatology.oxfordjournals.org .9) 6.7 (6.9)
7.4 (7) SJC (28) .7) 1 (0.6) . Therefore, the HL group maintained EULAR response, whereas the NL group suffered a significant loss of EULAR response, although the results were not significant, probably due to the small sample size. Finally, we performed a logistic regression analysis to identify which parameters were associated with maintenance of response. Of the baseline parameters (age, sex, disease duration, RF, ACPA, HAQ, ESR, CRP, DAS-28, sTNFR2 and DS-TNFR2), only ACPA titres were associated with maintenance of EULAR response with an odds ratio (OR) of 1.001; 95% CI 1.000, 1.002; P = 0.035.
Higher levels of DS-TNFR2 might reduce radiographic progression
In Cohort 1, 23.5% (12/52) of patients developed radiographic progression. We found no correlation between radiographic progression and serum levels of DS-TNFR2 or sTNFR2 at baseline; however, patients without radiographic progression tended to have higher mean levels of DS-TNFR2 at baseline than patients with progression, but the difference was not statistically significant [236 (290) vs 67 (132) ng/ml, respectively; P = 0.1, MannWhitney test]. The lack of significance may be due to the small sample size. In contrast, the mean of DS-TNR2 levels from baseline to 12 months was significantly different between patients with and without progression [43 (74) vs 171 (220) ng/ml, respectively; P = 0.007], and all patients who progressed had DS-TNFR2 levels of <65 ng/ml. Because DS-TNFR2 levels at baseline correlated with the levels at 12 months (r = 0.84; P < 0.05), these findings suggest that low levels of DS-TNFR2 could be a marker of radiographic progression. Finally, only 1/12 (8.3%) patients with HLs at baseline and at the end of follow-up showed radiographic progression compared with 3/9 (33%) patients with levels <50 ng/ml.
Serum levels of MMP-1 at baseline significantly correlated with the number of erosions [area under the curve (AUC) 0.714 (0.077) (0.5640.865); P = 0.02], the Larsen score (P = 0.04) and radiographic progression (P = 0.04) at the end of follow-up.
High baseline DS-TNR2 levels were associated with markers of RA severity In Cohort 1, 21/52 (40.4%) patients had HLs. In the HL group, all patients were RF + , and 85.7% were ACPA + , compared with 67 and 58.4%, respectively, in the NL group (P = 0.0001 and P = 0.034, respectively). In addition, patients with HLs had higher titres of RF and ACPA than patients with NLs (RF: 345 vs 87 UI/ml, respectively, P = 0.003; and ACPA: 809 vs 442 UI/ml, respectively; P = 0.04 Baseline DS-TNFR2 levels correlated with markers of disease activity
In Cohort 1, DS-TNFR2 levels correlated positively with sTNFR2 levels at baseline and at Week 52 (P < 0.001).
In Cohort 2, DS-TNFR2 levels correlated significantly with DAS-28 (P < 0.05), mHAQ (P < 0.05) and, especially, sTNFR2 levels (r = 0.904, r = 0.936, r = 0.867; P < 0.001 at Weeks 0, 6 and 30, respectively).
Discussion
In the early untreated RA Cohort 1, we analysed the effect of high DS-TNFR2 levels on the DMARD response and radiographic progression. In the established RA Cohort 2, we analysed the effects of high DS-TNFR2 levels on the response to anti-TNF-a therapy. To examine differences in the capacity to block serum TNF-a, we arbitrarily divided patients into groups with HLs or NLs of DS-TNFR2 ( > 50 ng/ml for HLs and 450 ng/ml for NLs). Consistent with the previous studies [15] , we found that the EULAR response to therapy was significantly higher in patients with early untreated RA than in patients with established RA. Our results suggest that HLs of DS-TNFR2 or sTNFR2 have clinical effects specifically in RA patients treated with anti-TNF-a (infliximab); these patients were able to maintain the EULAR response at Week 6 through Week 30 more often than patients with NLs. However, we found no significant differences in EULAR response between the HL and NL groups, probably due to the small sample size. Maintenance of EULAR response was significantly and positively associated with ACPA titres. To our knowledge, this is the first report to describe this effect.
These effects might be mediated through TNF-a inhibition and a carrier effect [16] . A previous study showed that etanercept, a fused protein of two sTNFR2 molecules linked to IgG1, could bind reversibly to TNF-a, and that the observed inhibition of TNF-a reflected a balance between the levels of etanercept, TNF-a and endogenous sTNFR [10] . Therefore, HLs of sTNFR2 might serve as a buffer for TNF-a levels; it may limit the effect of anti-TNF-a therapy in the induction phase, but then maintain relatively low TNF-a levels when the frequency of drug administration is reduced. This effect appeared to be specific for anti-TNF-a therapy, as we found no differential effects of high DS-TNFR2 levels on the response to synthetic DMARDs.
MMP-1 levels at baseline could predict radiographic progression at Week 52. Although our sample size with radiographic progression was rather small, our results support previous findings that MMP-1 is a biomarker of joint destruction [17, 18] . In contrast, when evaluated in the entire group, neither sTNFR2 nor DS-TNFR2 levels were associated with radiographic progression; however, patients with HLs of DS-TNFR2 (or sTNFR2) had less radiographic progression than patients with NLs. Our results should be interpreted with caution, due to the small number of patients; nevertheless, they suggest that high levels of DS-TNFR2 might have a protective effect on radiographic progression, perhaps through inhibition of TNF-a signalling. Further studies with larger sample sizes and longer study periods are necessary to appropriately evaluate the potentially protective effect of high sTNFR2 or DS-TNFR2 levels.
This study also found that high levels of serum DS-TNFR2 were associated with greater disease severity, as indicated by RF and ACPA levels [19] . In addition, DS-TNFR2 correlated consistently with several clinical and biological parameters of disease activity, consistent with previous studies showing a relationship between sTNFR2 levels and disease activity in RA [6, 2022] .
It remains to be determined why some patients generate very high levels of sTNFR2 by alternative splicing. In this study, patients with HLs or NLs did not differ in age, sex, disease duration or disease activity. Previous studies have found that, in established RA, circulating levels of sTNFR are associated with the T676G polymorphism in exon 6 of the TNFR2 gene, which results in a non-conservative amino acid substitution (methionine to arginine, M196R). This suggests that TNFR2-associated gene regulation may play a role in determining sTNFR levels in RA [23, 24] .
In conclusion, we confirmed that sTNFR2 produced by alternative splicing (DS-TNFR2) is the major constituent in RA patients with high levels of sTNFR2. These patients maintained a prolonged response specific to anti-TNF-a therapy, which was only associated with ACPA levels at baseline. Furthermore, radiographic progression might develop more slowly in patients with high levels of sTNFR2 than in patients with normal levels. However, due to the limitations of sample size and study duration, our findings should be confirmed in larger prospective studies. Future studies of prognostic markers of RA may reconcile the apparently beneficial effects of high DS-TNFR2 or sTNFR2 levels found in this study with the detrimental effects suggested in previous reports.
Rheumatology key messages
. Serum DS-TNFR2 levels represent 70% of high sTNFR2 levels. . Low levels of DS-TNFR2 or sTNFR2 are associated with secondary failure of anti-TNF therapy with infliximab. . Patients with high levels of DS-TNFR2 or sTNFR2 may have less radiographic progression.
